ASP Isotopes Q1 EPS Misses by $0.70 While Revenue Beats, Eyes $300M EBITDA
ASP Isotopes posted Q1 2026 EPS of -$0.84 versus consensus of -$0.14 while delivering revenue of $2.3 million compared to estimates of $2.03 million. The company holds $333 million cash with a 12.18 current ratio and plans first commercial shipments in 2026 targeting $300 million EBITDA by 2031.
1. Q1 2026 Financial Performance
ASP Isotopes posted Q1 2026 EPS of -$0.84 against analyst expectations of -$0.14 and generated $2.3 million in revenue versus $2.03 million forecast, reflecting mixed operational results.
2. Growth Outlook and Guidance
The company plans to commence commercial shipments in 2026 and projects achieving over $300 million in EBITDA by 2031, signaling confidence in long-term growth prospects.
3. Strong Financial Position
With $333 million in cash and equivalents and a current ratio of 12.18, ASP Isotopes has ample liquidity to support its commercial rollout and expansion plans.